Skip to main content
SpringerLink
Log in

Nonalcoholic Fatty Liver Disease (NAFLD) Association with Pediatric Diabetes

  • Chapter
  • First Online:
Diabetes in Children and Adolescents

Part of the book series: Contemporary Endocrinology ((COE))

  • 766 Accesses

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common liver disease in pediatrics. NAFLD is a chronic condition that predisposes to the development of cirrhosis and hepatocellular carcinoma. There is a strong link between NAFLD and type 2 diabetes in adults and adolescents, while some studies suggest that subjects with type 1 diabetes might be protected against the development of NAFLD. In this chapter, we review the pathophysiology and the clinical characteristics of NAFLD in pediatric groups as well as the current treatments being tested.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.01.048.

  2. Schwimmer JB, et al. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500–5. https://doi.org/10.1067/s0022-3476(03)00325-1.

    Article  PubMed  Google Scholar 

  3. Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115:e561–5. https://doi.org/10.1542/peds.2004-1832.

    Article  PubMed  Google Scholar 

  4. Browning JD, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. https://doi.org/10.1002/hep.20466.

    Article  PubMed  Google Scholar 

  5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31. https://doi.org/10.1056/NEJMra011775.

    Article  CAS  PubMed  Google Scholar 

  6. Feldstein AE, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538–44. https://doi.org/10.1136/gut.2008.171280.

    Article  CAS  PubMed  Google Scholar 

  7. Adams LA, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21. https://doi.org/10.1053/j.gastro.2005.04.014.

    Article  PubMed  Google Scholar 

  8. Donnelly KL, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–51. https://doi.org/10.1172/jci23621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. D’Adamo E, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33:1817–22. https://doi.org/10.2337/dc10-0284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lavine JE, Schwimmer JB. Pediatric initiatives within the Nonalcoholic Steatohepatitis-Clinical Research Network (NASH CNR). J Pediatr Gastroenterol Nutr. 2003;37:220–1. https://doi.org/10.1097/00005176-200309000-00002.

    Article  PubMed  Google Scholar 

  11. Newton KP, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 2016;170:e161971. https://doi.org/10.1001/jamapediatrics.2016.1971.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Samuel VT, Shulman GI. Nonalcoholic fatty liver disease, insulin resistance, and ceramides. N Engl J Med. 2019;381:1866–9. https://doi.org/10.1056/NEJMcibr1910023.

    Article  PubMed  Google Scholar 

  13. Kusminski CM, Scherer PE. Lowering ceramides to overcome diabetes. Science. 2019;365:319–20. https://doi.org/10.1126/science.aax6594.

    Article  CAS  PubMed  Google Scholar 

  14. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315:215–9. https://doi.org/10.1056/nejm198607243150402.

    Article  CAS  PubMed  Google Scholar 

  15. Trico D, et al. Metabolic features of nonalcoholic fatty liver (NAFL) in obese adolescents: findings from a multiethnic cohort. Hepatology. 2018;68:1376–90. https://doi.org/10.1002/hep.30035.

    Article  CAS  PubMed  Google Scholar 

  16. Al-Hussaini AA, Sulaiman NM, Alzahrani MD, Alenizi AS, Khan M. Prevalence of hepatopathy in type 1 diabetic children. BMC Pediatr. 2012;12:160. https://doi.org/10.1186/1471-2431-12-160.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gaiani S, et al. Nonalcoholic fatty liver disease (NAFLD) in nonobese patients with diabetes: prevalence and relationships with hemodynamic alterations detected with Doppler sonography(). J Ultrasound. 2009;12:1–5. https://doi.org/10.1016/j.jus.2008.12.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Targher G, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53:713–8. https://doi.org/10.1016/j.jhep.2010.04.030.

    Article  CAS  PubMed  Google Scholar 

  19. Targher G, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37:1729–36. https://doi.org/10.2337/dc13-2704.

    Article  CAS  PubMed  Google Scholar 

  20. Li TT, et al. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. Diabetes Metab. 2018. https://doi.org/10.1016/j.diabet.2018.03.002.

  21. Harman DJ, et al. Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. Hepatology. 2014;60:158–68. https://doi.org/10.1002/hep.27098.

    Article  PubMed  Google Scholar 

  22. Cusi K, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017;19:1630–4. https://doi.org/10.1111/dom.12973.

    Article  CAS  PubMed  Google Scholar 

  23. Llaurado G, et al. Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. J Clin Endocrinol Metab. 2015;100:607–16. https://doi.org/10.1210/jc.2014-3050.

    Article  CAS  PubMed  Google Scholar 

  24. Petit JM, et al. Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis. Diabet Med. 2015;32:1648–51. https://doi.org/10.1111/dme.12805.

    Article  CAS  PubMed  Google Scholar 

  25. Schwimmer JB, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial. JAMA. 2019;321:256–65. https://doi.org/10.1001/jama.2018.20579.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Van Name MA, et al. A low omega-6 to omega-3 PUFA ratio (n-6:n-3 PUFA) diet to treat fatty liver disease in obese youth. J Nutr. 2020. https://doi.org/10.1093/jn/nxaa183.

  27. Lavine JE, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–68. https://doi.org/10.1001/jama.2011.520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Schwimmer JB, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016;151:1141–1154.e1149. https://doi.org/10.1053/j.gastro.2016.08.027.

    Article  CAS  PubMed  Google Scholar 

  29. Belfort R, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–307. https://doi.org/10.1056/NEJMoa060326.

    Article  CAS  PubMed  Google Scholar 

  30. Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90. https://doi.org/10.1016/s0140-6736(15)00803-x.

    Article  CAS  PubMed  Google Scholar 

  31. Dong Y, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284–95. https://doi.org/10.1016/j.clinre.2016.11.009.

    Article  CAS  PubMed  Google Scholar 

  32. Eriksson JW, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923–34. https://doi.org/10.1007/s00125-018-4675-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kuchay MS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801–8. https://doi.org/10.2337/dc18-0165.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale-New Haven Children’s Hospital, Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA

    Nicola Santoro, Rachel Goldberg-Gel & Sonia Caprio

Authors
  1. Nicola Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Goldberg-Gel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonia Caprio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Santoro .

Editor information

Editors and Affiliations

  1. Yale-New Haven Children’s Hospital, Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA

    William V. Tamborlane

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Santoro, N., Goldberg-Gel, R., Caprio, S. (2021). Nonalcoholic Fatty Liver Disease (NAFLD) Association with Pediatric Diabetes. In: Tamborlane, W.V. (eds) Diabetes in Children and Adolescents. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-64133-7_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-64133-7_17

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-64132-0

  • Online ISBN: 978-3-030-64133-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation